Elshal Mahmoud, Abu-Elsaad Nashwa, El-Karef Amr, Ibrahim Tarek Mostafa
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, El Gomhoria street, Mansoura, Eldakahlia, 33651, Egypt.
Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1293-304. doi: 10.1007/s00210-015-1157-7. Epub 2015 Aug 14.
Tyrosine kinase inhibitors have been emerged recently as an effective therapy against liver fibrosis. The current study was designed to test a potential anti-fibrotic effect of the multi-targeted receptor tyrosine kinase inhibitor pazopanib. Carbon tetrachloride (CCl4; 1 mL/kg) was injected intraperitoneally (i.p.) twice/week for 8 weeks. Pazopanib (10 and 30 mg/kg, i.p.) was administered three times/week at the beginning of week 5. Levels of liver function biomarkers (alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, and total bilirubin), malondialdehyde, transforming growth factor-β1 (TGF-β1), caspase-3, factor-related apoptosis (FAS), vascular endothelial growth factor (VEGF) receptor-1, and pigment endothelial derived factor (PEDF) were measured. The tissue level of the inflammatory cytokines IL-6 and tumor necrosis factor-α (TNF-α) were assigned. Fibrotic area was measured by morphometry and expression of alpha-smooth muscle actin (α-SMA), caspase-3, platelet-derived growth factor (PDGF) receptor-β, and matrix metalloproteinase-2 (MMP-2) was scored immunohistochemically. Hepatic expression of collagen-1-alpha-1 (Col1A1) and tissue inhibitor metalloproteinase-1 (TIMP-1) mRNA were assigned by RT-qPCR. Injection of CCl4 resulted in marked collagen deposition, necroinflammation, and fibrosis (2.67%). Pazopanib in a dose of 30 mg/kg improved liver function, reduced fibrosis (1.48%), and decreased significantly (P < 0.01) liver expression of malondialdehyde, TGF-β1, IL-6, TNF-α, Col1A1, TIMP-1, α-SMA, MMP-2, PDGF receptor-β, and VEGF receptor-1. Additionally, the apoptotic markers (caspase-3, FAS) and the anti-angiogenic factor PEDF were upregulated significantly (P < 0.05). Pazopanib at a certain dose level can halt liver fibrosis progression through modulating inflammatory cytokines, suppressing stellate cell activity, inducing apoptosis, and potentially regulating angiogenesis.
酪氨酸激酶抑制剂最近已成为治疗肝纤维化的一种有效疗法。本研究旨在测试多靶点受体酪氨酸激酶抑制剂帕唑帕尼的潜在抗纤维化作用。每周两次腹腔注射四氯化碳(CCl4;1 mL/kg),持续8周。在第5周开始时,每周三次腹腔注射帕唑帕尼(10和30 mg/kg)。检测肝功能生物标志物(丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、白蛋白和总胆红素)、丙二醛、转化生长因子-β1(TGF-β1)、半胱天冬酶-3、凋亡相关因子(FAS)、血管内皮生长因子(VEGF)受体-1和色素内皮衍生因子(PEDF)的水平。测定炎症细胞因子白细胞介素-6和肿瘤坏死因子-α(TNF-α)的组织水平。通过形态计量法测量纤维化面积,并对α-平滑肌肌动蛋白(α-SMA)、半胱天冬酶-3、血小板衍生生长因子(PDGF)受体-β和基质金属蛋白酶-2(MMP-2)的表达进行免疫组织化学评分。通过逆转录定量聚合酶链反应(RT-qPCR)测定Ⅰ型胶原α1链(Col1A1)和金属蛋白酶组织抑制剂-1(TIMP-1)mRNA的肝脏表达。注射CCl4导致明显的胶原沉积、坏死性炎症和纤维化(2.67%)。30 mg/kg剂量的帕唑帕尼改善了肝功能,减少了纤维化(1.48%),并显著降低(P < 0.01)肝脏中丙二醛、TGF-β1、白细胞介素-6、肿瘤坏死因子-α、Col1A1、TIMP-1、α-SMA、MMP-2、PDGF受体-β和VEGF受体-1的表达。此外,凋亡标志物(半胱天冬酶-3、FAS)和抗血管生成因子PEDF显著上调(P < 0.05)。一定剂量水平的帕唑帕尼可通过调节炎症细胞因子、抑制星状细胞活性、诱导凋亡以及潜在地调节血管生成来阻止肝纤维化进展。